| Suggest |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Medicine > Rimonabant: A Weapon to Fight Back Obesity |
|
Suggest - Rimonabant: A Weapon to Fight Back Obesity
Obesity is a pervasive disease spanning across all age groups worldwide. To stop it, Rimonabant (Acomplia) die According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product t pill helps an individual by suppressing his appetite for food intake. Yet, the real medicine lies in the exe ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in rcises and the controlled diet program that one follows along with Rimonabant (Acomplia) medication. Rimonaba lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nt (Acomplia) is an anti-obesity drug developed by Sanofi-Aventis, a French pharmaceutical firm. It is markete here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe under the name of Acomplia in the UK and EU. Though it has yet not got received approval from the FDA (Food a d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nd Drug Administration) for retailing in the US. It contemplated to be approved from for sale in US it might ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc be marketed as Zimulti. Earlier the manufacturer had professed that with Rimonabant (Acomplia), one can also e easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ade smoking habit. But of late they are keeping quite on that claim. Rimonabant is an appetite suppressant by nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically nature. It selectively blocks CB1 receptors found in brain and other organs in close proximity, which regulat and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ e glucose and lipid metabolism. The drug aids in normalising the over activity of the Endo-Cannabinoid (EC) sy ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi tem. Endo-Cannabinoid system, displays an important role in regulating energy balance and body mass. Some of ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a the widespread side effects linked with the usage of Acomplia (Rimonabant) are nausea, headache, dizziness and dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod depression amongst others. These side effects are mild and subside once you adjust to the drug. A person shou cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ld always consult a doctor before going for the drug. A doctor is the right person to decide what will work ou tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen for him. Breast-feeding mothers and pregnant women should discuss with a doctor before taking the drug. Your t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel doctor should be informed about your medical history including heart ailments, diabetes, asthma, allergy or bl ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ood pressure to avoid contraindication of Rimonabant (Acomplia) medication. Due to the recent availability of y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products the drug, the results of its effects are not accessible as for now. However with time the outcome would become . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de more discernible. It can be hard to locate pharmacists who sell Rimonabant (Acomplia) it in the UK or EU. Yo elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip u can ease your search with the aid of online pharmacies, which are an easy and quick option to buy Rimonabant tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Work From Home: Take the Two Minute Commute to Your Home Office Article Marketing for the Purpose of Building Links I Hit or Miss? How to Perform a Background Check on a Potential Online Date
|